MORPHINE-6-GLUCURONIDE DISPOSITION IN RENAL IMPAIRMENT

被引:43
|
作者
HANNA, MH
DCOSTA, F
PEAT, SJ
FUNG, C
VENKAT, N
ZILKHA, TR
DAVIES, S
机构
[1] Pain Releif Research Unit, Department of Anaethesia, King's college Hospital, London SE5 9RS, Denmark Hill
关键词
ANALGESICS; MORPHINE-6-GLUCURONIDE; KIDNEY; PERITONEAL DIALYSIS; RENAL FAILURE; PHARMACOKINETICS;
D O I
10.1093/bja/70.5.511
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Twelve patients with chronic renal failure (dialysis-dependent) and six with good renal function after renal transplantation received i.v. morphine-6-glucuronide (M6G) 30 mug kg-1 as part of a standardized anaesthetic technique for minor surgery. Continuous peritoneal dialysis was commenced 6 h after M6G administration in six of the dialysis-dependent patients. Serum was sampled for up to 12 h and analysed for morphine and M6G by high pressure liquid chromatography. Morphine was not detected. Mean (SD) derived pharmacokinetic variables for the three groups (transplant, renally impaired non-dialysed and renally impaired dialysed, respectively) were: elimination haff-life 2.14 (0.69) h, 27.10 (15.8) h, 17.33 (4.6) h; clearance 96.0 (34.9) ml min-1, 10.57 (5.57) ml min-1, 14.3 (6.2) ml min-1; volume of distribution 0.19 (0,03) litre kg-1, 0.25 (0.06) litre kg-1, 0.27 (0.06) litre kg-1. The elimination half-life was shorter (P < 0.01) and the clearance greater (P < 0.01) for the transplanted group compared with the dialysed and non-dialysed groups. Peritoneal dialysis for the second 6 h after drug administration had little effect on M6G disposition as assessed by comparison with data obtained from the non-dialysed group.
引用
收藏
页码:511 / 514
页数:4
相关论文
共 50 条
  • [31] Heroin-using drivers: importance of morphine and morphine-6-glucuronide on late clinical impairment
    Liliana Bachs
    Gudrun Høiseth
    Svetlana Skurtveit
    Jørg Mørland
    European Journal of Clinical Pharmacology, 2006, 62 : 905 - 912
  • [32] MODULATION OF METABOLIC EFFECTS OF MORPHINE-6-GLUCURONIDE BY MORPHINE-3-GLUCURONIDE
    HASHIGUCHI, Y
    MOLINA, PE
    ABUMRAD, NN
    BRAIN RESEARCH BULLETIN, 1995, 38 (04) : 325 - 329
  • [33] BIOCHEMICAL BASIS FOR ANALGESIC ACTIVITY OF MORPHINE-6-GLUCURONIDE .1. PENETRATION OF MORPHINE-6-GLUCURONIDE IN BRAIN OF RATS
    YOSHIMURA, H
    IDA, S
    OGURI, K
    TSUKAMOTO, H
    BIOCHEMICAL PHARMACOLOGY, 1973, 22 (12) : 1423 - 1430
  • [34] RENAL TUBULAR TRANSPORT OF MORPHINE, MORPHINE-6-GLUCURONIDE, AND MORPHINE-3-GLUCURONIDE IN THE ISOLATED PERFUSED RAT-KIDNEY
    VANCRUGTEN, JT
    SALLUSTIO, BC
    NATION, RL
    SOMOGYI, AA
    DRUG METABOLISM AND DISPOSITION, 1991, 19 (06) : 1087 - 1092
  • [35] Peripheral analgesic effects of morphine-6-glucuronide
    Meier, S
    Tegeder, I
    Geisslinger, G
    Lötsch, J
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 365 : R108 - R108
  • [36] PERSISTENTLY INCREASED MORPHINE-6-GLUCURONIDE CONCENTRATIONS
    CALLEJA, MA
    CHILDS, D
    VENN, RF
    MICHALKIEWICZ, A
    BRITISH JOURNAL OF ANAESTHESIA, 1990, 64 (05) : 649 - 649
  • [37] MORPHINE-6-GLUCURONIDE, A POTENT MU AGONIST
    PASTERNAK, GW
    BODNAR, RJ
    CLARK, JA
    INTURRISI, CE
    LIFE SCIENCES, 1987, 41 (26) : 2845 - 2849
  • [38] Influence of Morbid Obesity on the Pharmacokinetics of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide
    Sjoerd de Hoogd
    Pyry A. J. Välitalo
    Albert Dahan
    Simone van Kralingen
    Michael M. W. Coughtrie
    Eric P. A. van Dongen
    Bert van Ramshorst
    Catherijne A. J. Knibbe
    Clinical Pharmacokinetics, 2017, 56 : 1577 - 1587
  • [39] Morphine and morphine-6-glucuronide in the plasma and cerebrospinal fluid of children
    Hain, RDW
    Hardcastle, A
    Pinkerton, CR
    Aherne, GW
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (01) : 37 - 42
  • [40] Contribution of morphine and morphine-6-glucuronide to respiratory depression in a child
    Hannam, J. A.
    Anderson, B. J.
    ANAESTHESIA AND INTENSIVE CARE, 2012, 40 (05) : 867 - 870